For first time, biologic shown to block coronavirus infection

22 January 2021

Eli Lilly (NYSE: LLY) has released positive results from a test of its monoclonal antibody bamlanivimab, in preventing people from contracting COVID-19.

In the Phase III BLAZE-2 study, the biologic was shown to significantly reduce the risk of contracting symptomatic COVID-19, for residents and staff of long-term care facilities.

While bamlanivimab has already been authorized for the treatment of mild to moderate COVID-19, the trial raises the prospect that Lilly’s investigational antibody could have a wider application in stopping infections.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK